A Phase IV, Randomized, Prospective, US-based, Multicenter, Cross-over Study Evaluating Subject Ease-of-use With Rebif Rebidose and Rebiject II Autoinjectors in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With REBIF 44 mcg Subcutaneously Three Times a Week

Trial Profile

A Phase IV, Randomized, Prospective, US-based, Multicenter, Cross-over Study Evaluating Subject Ease-of-use With Rebif Rebidose and Rebiject II Autoinjectors in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With REBIF 44 mcg Subcutaneously Three Times a Week

Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Mar 2017

At a glance

  • Drugs Interferon beta-1a (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Sponsors EMD Serono
  • Most Recent Events

    • 17 Sep 2016 Results presented at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis
    • 29 Mar 2016 Status changed from recruiting to completed according to the ClinicalTrials.gov record.
    • 16 Sep 2015 Planned End Date changed from 1 Nov 2015 to 1 Apr 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top